Hantavirus Global Situational Briefing — July 8, 2026

Argentina is still the main quantitative hantavirus watchpoint this morning, and the Nepal signal should be downgraded from "possible outbreak" to "unverified report corrected by the publisher." Argentina's latest national bulletin table records 51 hantavirosis cases in 2026 through epidemiological week 25, above the 2022-2025 median of 31 for the same point in the year and still above expected levels in the most recent four-week window. 1 A corrected Republica report says Nepal's Health Ministry dismissed media claims of a hantavirus outbreak, with no confirmed infection or community outbreak reported in the country. 2

Signal table

Signal	Latest source-backed status	Operational read
Argentina national surveillance	51 hantavirosis cases recorded for 2026 through SE25, compared with a 2022-2025 median of 31; the event is marked above expected both year-to-date and in the last four weeks. 1	Keep Argentina as the highest-priority national watchpoint, especially Buenos Aires, Salta, and other provinces already identified in the detailed seasonal review.
Nepal media correction	The earlier report of a first hantavirus death has been removed by Republica; the correction says the Ministry described the outbreak claims as unverified and baseless. 2	Treat Nepal as an information-quality item, not as a confirmed outbreak signal, until a ministry-hosted notice or laboratory-confirmed case record appears.
M/V Hondius Andes virus event	WHO's 2 July update holds the event at 13 cases, including 12 confirmed and one probable case, with three deaths; all identified contacts completed 42-day follow-up and WHO says no further related transmission is expected. 3	The ship-linked event remains in response-closure and investigation mode, not active spread mode.
United States monitoring	CDC said all monitored U.S. contacts completed the 42-day period without developing hantavirus disease. 4	No U.S. outbreak-related disease signal is active; scientific source-investigation work continues.
EU/EEA risk	ECDC's outbreak page still lists 13 total cases and assesses the EU/EEA general-population risk as very low; its week 27 CDTR did not carry a new hantavirus item. 5 6	Europe remains in follow-up and preparedness posture, with no new EU/EEA escalation in the latest public weekly threat list.

Nepal: downgrade the rumor, keep the verification slot open

The Nepal item matters because it changes the status of a previous watchpoint. Republica's corrected story says its earlier report of a hantavirus alert after Nepal's first reported death was based on information that was not adequately verified and has since been removed. The same page quotes the Health Ministry as saying there is no confirmed hantavirus infection and no community outbreak in the country. 2

That does not prove Nepal has zero future risk. It does change how this monitor should classify the item. A corrected media report quoting a ministry statement is enough to demote the earlier death report from "watch for confirmation" to "do not treat as confirmed." It is not strong enough to become a permanent official country endpoint, because the ministry statement was not captured here as a ministry-hosted primary document.

For the next update, the clean evidence would be one of three things: a Ministry of Health notice, a WHO country-office statement, or a laboratory-confirmed case record. Until then, Nepal should not be counted in global case totals.

Argentina: above-expected activity remains the live surveillance issue

Argentina's newest national bulletin table gives the clearest active official signal. Through SE25, the BEN table lists 51 hantavirosis cases for 2026, versus a 2022-2025 median of 31 for the same period. The table also flags the event as above expected for both the year-to-date view and the last four weeks. 1

The more detailed BEN 812 review, published for SE22, explains why the Argentine signal deserves attention. For the 2025-2026 season through SE22, Argentina reported 108 confirmed hantavirosis cases and 36 deaths, a case fatality of 33.3%. The same review says the current season's national incidence, 0.23 cases per 100,000 population, was the highest in the analyzed period through that epidemiological week. 7

The seasonal distribution is not uniform. BEN 812 places most 2025-2026 seasonal cases in Buenos Aires, with 44 cases, followed by Salta with 32, Santa Fe and Jujuy with seven each, Rio Negro with six, and Entre Rios and Chubut with five each. 7 Mortality was also concentrated: Buenos Aires accounted for 18 of the 36 seasonal deaths, while Salta accounted for 12 and had the highest jurisdictional mortality rate in the table, 7.90 deaths per 1,000,000 population. 7

Two readings can coexist here. First, Argentina remains above its recent expected range. Second, this is still a surveillance and case-management problem rather than evidence of a new internationally spreading event. The latest BEN summary table adds to the national watch signal, but it does not change the contained status of the M/V Hondius outbreak.

M/V Hondius: contained, with two unresolved follow-up threads

WHO's current Disease Outbreak News remains the governing source for the cruise-linked Andes virus event. It reports 13 total ship-linked cases, three deaths, 317 high-risk contacts who completed quarantine and monitoring, and 336 low-risk contacts who completed self-monitoring. WHO says completion of follow-up without additional secondary cases confirms containment and that the outbreak no longer poses a public-health risk. 3

CDC's U.S. response transcript is consistent with that closure posture. CDC said all U.S. citizens identified as potentially exposed completed monitoring without developing disease, while CDC scientists continued work with Argentine partners on possible source investigation, including rodent trapping and testing in areas connected to the outbreak. 4

Two threads remain open, but neither is an active spread signal. WHO still lists two hospitalized cases as undergoing medical treatment in the 2 July update. 3 WHO also says investigations continue into the exact source and route of exposure, including genomic sequencing of surveillance cases in Chile and Argentina and environmental sampling after disembarkation. 3

Regional preparedness: the Andes countries are treating this as a systems problem

The most useful regional preparedness signal this week is not a new case count. ORAS-CONHU, the Andean Health Organization, convened more than 80 public-health, surveillance, zoonosis, and laboratory specialists for a subregional technical meeting on hantavirus surveillance, laboratory diagnosis, and exposure-risk control in endemic zones. 8

The meeting's framing is useful for risk assessment. ORAS-CONHU links the preparedness push to sustained increases in South American cases over the past two years, Andes virus activity in Chile and Argentina, Laguna Negra virus activity in Bolivia and Paraguay, and the recent MV Hondius alert. It also notes concern that heavier rainfall associated with El Nino conditions toward late 2026 and early 2027 could raise zoonotic and rodent-borne disease risk. 8

That makes the Andean signal different from a single outbreak bulletin. It points to a cross-border surveillance agenda: human case detection, rodent ecology, diagnostic capacity, and border-area cooperation.

Science watch: the countermeasure gap is still the weak point

A June review in npj Viruses summarizes the countermeasure problem clearly: no vaccine or therapeutic is licensed for Andes virus, even though ANDV is the hantavirus species with documented human-to-human transmission. The review notes that China and South Korea use inactivated vaccines against Hantaan and Seoul viruses, but those products do not solve the Andes virus problem. 9

The same review says several ANDV vaccine platforms have worked in preclinical models, including viral-vectored, DNA-based, RNA-based, and nanoparticle candidates. A DNA vaccine encoding ANDV glycoprotein has also been tested in a small phase 1 trial and was reported safe and immunogenic after three or four needle-free immunizations. 9

For treatment, the picture is thinner. Supportive care remains the practical standard for hantavirus cardiopulmonary syndrome, while ribavirin, favipiravir, monoclonal antibodies, and immune sera remain limited by missing or incomplete human efficacy data for HCPS. 9 This is why source investigation and early case recognition still matter so much: the response toolbox is mostly surveillance, exposure reduction, isolation, contact management, and intensive supportive care.

Watchlist for the next 24 hours

Argentina BEN and provincial updates: the next useful change would be a newer BEN detailed hantavirosis section, or provincial updates from Buenos Aires, Salta, Chubut, Rio Negro, or Santa Fe.
Nepal primary-source confirmation: the earlier reported death should remain excluded unless a ministry-hosted bulletin, WHO notice, or laboratory confirmation appears.
Chile surveillance: wait for a readable official bulletin before adding current Chile counts; do not infer country totals from search-result snippets or reposts.
M/V Hondius clinical outcomes: final status of the two cases WHO still listed as under treatment remains an open follow-up item.
Rodent and climate-risk signals: Andean countries' surveillance, El Nino-linked rainfall risk, and field sampling results are the highest-value ecological indicators to watch next.